Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapy.

ABSTRACT:

Objective

To assess retention, tolerability, and safety, efficacy and effects on quality of life (QoL) of eslicarbazepine acetate (ESL) add-on treatment over 6 months in a real-world adult population with partial-onset seizures.

Methods

This non-interventional, multicenter, prospective study was performed in eight European countries. Adult patients (n = 247) for whom the physician had decided to initiate ESL as add-on to an existing antiepileptic drug (AED) monotherapy were invited to participate. The study comprised three visits: baseline, and after 3 and 6 months. Data on ESL retention, efficacy, tolerability, safety, and QoL were collected.

Results

After 6 months, the retention rate of ESL was 82.2%, and 81.8% of patients reported a reduction of seizure frequency o

SUBMITTER: Holtkamp M 

PROVIDER: S-EPMC5067651 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature